|

S103 cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Xijing Hospital1

Indications

  • Refractory Multiple Sclerosis1
  • Multiple Sclerosis (MS) Secondary Progressive1
  • Multiple Sclerosis (MS) Primary Progressive1
  • Multiple Sclerosis1

Other1 trial

Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.